Cancer medicine · 2026
Artesunate Induces G0/G1 Phase Arrest in Tumor Cells and Associates With Cyclin-Dependent Kinase 4 (CDK4).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chi Xinyu, Chen Qicong, Wang Gang, Luo Honglin, Qu Shenhong, Zou Xiaosu
Аннотация
BACKGROUND: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Cyclin-dependent kinase 4 (CDK4) is a well-validated oncogenic driver in NSCLC, yet current CDK4 inhibitors-predominantly based on the aminopyrimidine scaffold-are limited by structural homogeneity and the rapid emergence of acquired resistance, underscoring the need for novel chemotypes.
METHODS: We employed a HuProt human proteome microarray to screen for direct cellular targets of artesunate, an FDA-approved artemisinin derivative. Candidate interactions were validated by molecular docking, surface plasmon resonance (SPR), and in vitro kinase assays. Functional effects were assessed in A549 and H1299 NSCLC cell lines using flow cytometry and Western blotting.
RESULTS: Artesunate was identified as a direct binder of CDK4, with molecular docking revealing a strong binding affinity (-7.069 kcal/mol). SPR analysis confirmed this interaction with a Kd of 488 μM, and in vitro kinase assays demonstrated potent inhibition of CDK4/Cyclin D3 activity (IC50 = 0.2943 μM). Treatment with artesunate induced significant G0/G1 cell cycle arrest in both A549 and H1299 cells. This effect was mediated through inhibition of the CDK4-Rb-E2F axis, as evidenced by dose-dependent suppression of Rb phosphorylation at Ser780 and Ser795.
CONCLUSION: Our findings establish artesunate as a structurally distinct, non-aminopyrimidine CDK4 inhibitor with potent biochemical and cellular activity in NSCLC models. This work provides a promising therapeutic strategy to circumvent resistance associated with current CDK4 inhibitors and supports the repurposing of artesunate for CDK4-driven cancers.
METHODS: We employed a HuProt human proteome microarray to screen for direct cellular targets of artesunate, an FDA-approved artemisinin derivative. Candidate interactions were validated by molecular docking, surface plasmon resonance (SPR), and in vitro kinase assays. Functional effects were assessed in A549 and H1299 NSCLC cell lines using flow cytometry and Western blotting.
RESULTS: Artesunate was identified as a direct binder of CDK4, with molecular docking revealing a strong binding affinity (-7.069 kcal/mol). SPR analysis confirmed this interaction with a Kd of 488 μM, and in vitro kinase assays demonstrated potent inhibition of CDK4/Cyclin D3 activity (IC50 = 0.2943 μM). Treatment with artesunate induced significant G0/G1 cell cycle arrest in both A549 and H1299 cells. This effect was mediated through inhibition of the CDK4-Rb-E2F axis, as evidenced by dose-dependent suppression of Rb phosphorylation at Ser780 and Ser795.
CONCLUSION: Our findings establish artesunate as a structurally distinct, non-aminopyrimidine CDK4 inhibitor with potent biochemical and cellular activity in NSCLC models. This work provides a promising therapeutic strategy to circumvent resistance associated with current CDK4 inhibitors and supports the repurposing of artesunate for CDK4-driven cancers.